The Value of F-18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for the Detection of Residual Breast Tumor or Axillary Metastasis after Neoadjuvant Chemotherapy in Invasive Ductal Carcinoma of the Breast | Zendy

Kezban Berberoğlu | Zendy

Open Access

The Value of F-18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for the Detection of Residual Breast Tumor or Axillary Metastasis after Neoadjuvant Chemotherapy in Invasive Ductal Carcinoma of the Breast

Author(s) -

Kezban Berberoğlu

Publication year - 2020

Publication title -

i̇stanbul medical journal

Language(s) - English

Resource type - Journals

ISSN - 2619-9793

DOI - 10.4274/imj.galenos.2020.88714

Subject(s) - axilla , medicine , breast cancer , positron emission tomography , radiology , metastasis , neoadjuvant therapy , standardized uptake value , breast carcinoma , chemotherapy , nuclear medicine , cancer

Cite this article as/Atıf: Berberoğlu K. The Value of F-18-fluorodeoxyglucose Positron Emission Tomography/ Computed Tomography for the Detection of Residual Breast Tumor or Axillary Metastasis after Neoadjuvant Chemotherapy in Invasive Ductal Carcinoma of the Breast.. İstanbul Med J 2020; 21(1): 42-6. Introduction: Accurate evaluation of pathological response after neoadjuvant chemotherapy would aid in treatment and surgical planning as well as prediction of outcomes. This study examined the value of F-18-fluorodeoxyglucose positron emission tomography/computed tomography (F-18-FDG PET/ CT) in predicting pathologically confirmed residual tumor in breast or presence of axillary metastasis when performed after completion of neoadjuvant therapy in patients with invasive ductal carcinoma (IDC) of the breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research